Pharma-Bio Serv (OTCMKTS:PBSV – Get Free Report) posted its earnings results on Monday. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.35, reports. The company had revenue of $2.47 million during the quarter, compared to the consensus estimate of $2.70 million. Pharma-Bio Serv had a negative net margin of 8.18% and a negative return on equity of 5.61%.
Pharma-Bio Serv Price Performance
OTCMKTS PBSV opened at $0.43 on Wednesday. The company has a market capitalization of $9.86 million, a PE ratio of -14.33 and a beta of 0.53. The company has a fifty day moving average of $0.55 and a 200 day moving average of $0.57. Pharma-Bio Serv has a 1 year low of $0.31 and a 1 year high of $0.90.
Pharma-Bio Serv Announces Dividend
The firm also recently announced a dividend, which will be paid on Thursday, March 20th. Investors of record on Friday, February 28th will be given a dividend of $0.075 per share. The ex-dividend date of this dividend is Friday, February 28th. Pharma-Bio Serv’s dividend payout ratio is presently -250.00%.
Pharma-Bio Serv Company Profile
Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies.
Featured Stories
- Five stocks we like better than Pharma-Bio Serv
- Basic Materials Stocks Investing
- 3 Energy Stocks With Cheap Valuations and Big Returns Ahead
- Breakout Stocks: What They Are and How to Identify Them
- 3 Stocks Returning Billions to Shareholders via Buybacks
- Energy and Oil Stocks Explained
- Tesla: 1 Reason to Love It, 1 Reason to Be Cautious
Receive News & Ratings for Pharma-Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma-Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.